To clarify the effectiveness of methylprednisolone pulse therapy on crescentic glomerulonephritis (CresGN), data of 46 patients was retrospectively studied. According to the slope of reciprocals of serum creatinine (s-Cr) the patients were divided into acute and insidious types, and each type was further divided into pulse (P) and conventional (C) therapy groups. In group C, sCr improved more frequently in the acute type (8/10) than in the insidious type (1/9, p<0.05), and the renal survival rate was somewhathigher in the former (p=0.09). In the acute type there was no difference in the improvement rate of s-Cr between the two therapy groups, whereas in the insidious type, the improvement rate was higher in group P (9/15) than in group C (1/9, p<0.05) and the renal survival rate was higher in the former (p<0.01). These results suggest that methylprednisolone pulse therapy may be highly effective for the insidious type of CresGN. (Internal Medicine 37: 585-591, 1998) 
Introduction
It is knownthat a majority of patients with crescentic glomerulonephritis (CresGN) follow a rapidly progressive course, terminating in end-stage renal failure within a period of several weeks or months (1-3). Recently, we reported that in CresGN, the reciprocal of serum creatinine (1/Cr) declined linearly and that CresGNcould be classified into two distinct types according to the rate of decline, i.e., acute versus insidious ("subacute": used in the previous report) types (4) . The former type has transient disease activity and follows a favorable clinical course in spite of rapid deterioration of renal function in the initial phase, while the latter showsa slow but steady deterioration of renal function with poor response to immunosuppressive treatment. Someauthors have suggested that methylprednisolone pulse therapy may be beneficial in patients with . However, because of potential life-threatening complications, high-dose corticosteroid therapy should be cautiously administered only in patients for whom conventional therapy is insufficient. Since it would be extremely difficult to conduct prospective controlled trials on this question, we retrospectively investigated whether pulse therapy offers significant advantages in the treatment of CresGNcompared with conventional regimens, and attempted to clarify the subset of patients for whom this type of therapy is appropriate.
Patients and Methods

Pa tien ts
Of the patients diagnosed as having CresGN by renal biopsy or autopsy at the KanazawaUniversity Hospital or affiliated hospitals between January 1971 and March 1997, 46 patients (male:female = 24:22) with a mean age of51.2 ± 3.1 (mean ± SE) years who fulfilled the following three criteria were studied: 1 ) more than 50% ofglomeruli observed by light microscopy had crescents; 2) serum creatinine (s-Cr) could be determined sequentially on three or more occasions before treatment; and 3) corticosteroids and/or immunosuppressive drugs were administered. As previously reported (4), these patients were divided into two clinical types as follows, according to the rate of decline of 1/Cr: the acute type (22 patients) with a rate of decline of 1.Ox1.0~2 dl/mg/day or greater, or with increments of s-Cr from 1.0 to 10.0 mg/dl within 90 days on the calculated regression line of 1/Cr; and the insidious (subacute) type (24 patients) with a more gradual rate of decline. 
Results
Clinical and pathological backgrounds Clinical and pathological backgrounds were compared between the acute and insidious types, and between groups P and C within each type. Betweenthe acute and insidious types, there were no differ- Table 1 . Clinical Data before Treatment mean ± SE, fmore than 3.5 g/day, fthigher than 140/90 mmHg. Table 1 ). The interval from disease onset to histological examination in the acute type (53.8 ± 7.4 days) was shorter than that in the insidious type (294.8 ± 50.9 days, p<0.01, Table 2 ). On pathological examination, despite the lack of difference in the percentage of crescent formation between the two types, the percentage of cellular crescents wassomewhathigher in the acutetype (61.0±7.4%) thaninthe insidious type (43.4±5.0%, p=0.06). Interstitial fibrosis was more severe in the insidious type (p<0.05), although there was no difference in interstitial cell infiltration between the two types. Between group P and C within each type, there were no differences in clinical or pathological parameters except for age (p<0.01), incidence of underlying diseases (p<0.05) and incidence of hypertension (p<0.05) in the acute type.
Effects of treatment Amongpatients treated with conventional therapy, the improvement rate ofs-Cr was higher in the acute type (8/10, 80%) than in the insidious type (1/9, 11%, p<0.05), and the renal survival rates at 1, 2 and 3 years of follow-up were somewhat higher in the acute type (79, 79 and 79%, respectively) than in the insidious type (44, 17 and 17%, p=0.09, Fig. 1 ). In the acute type there was no difference in the improvement rate of s-Cr between groups P (8/12, 67%) and C (8/10, 80%, Table 3 ). Out of 16 improved patients, 4 began chronic dialysis after 63.5 ± 24.0 months, and 12 had a mean s-Crlevel of 1.6 ± 0.2 mg/dl after 55.9 ± 18.7 months. The renal survival rates at 1, 2 and 3 years of follow-up in group P (74, 74 and 56%, Follow-up period after treatment (months) respectively) were comparable to those in group C (79, 79 and 79%, Fig. 2, top) .
In contrast, in the insidious type, the improvementrate was higher in group P (9/15, 60%) than in group C (1/9, 11%, p<0.05, Table 3 ). No serious complications were observed during or after pulse therapy. In group P, there were no differences in clinical and pathological parameters between the 9 improved and 6 unimproved patients, including s-Cr before treatment (3.8 ± 0.6 vs. 2.6 ± 0.4 mg/dl). No differences in the improvementrate were noted between 3 patients with systemic diseases (2/3, 67%) and 12 with IgA nephropathy or no underlying diseases (7/12, 58%). In group P, one improved and Follow-up period after treatment (months) one unimproved patient died after 9 and 5 months, respectively, and 2 improved and 4 unimproved patients ultimately required chronic dialysis after 38.7 ± 10.3 months. The other 6 improved and one unimproved patient had stable renal function with a mean s-Cr level of 1.9 ± 0.3 mg/dl after 54.4 ± 14.2 months. In group C, 7 out of 8 unimproved patients started chronic dialysis after 8.9 ± 2.3 months. Follow-up biopsy performed in 6 improved patients of group P after a mean interval of 62.5 ± 10.4 days after the initial biopsy revealed a significant decrease in the percentage of crescentic glomeruli from 89.5 ± 5.4 to 70.1 ± 7.6% (p<0.01) and disappearance of cellular crescents except in one patient (no. 24, Fig. 3 ). No progression of interstitial fibrosis wasobserved except in one patient (no. 24). The renal survival rates at 1, 2 and 3 years of follow-up were 100, 83 and 63%, respectively, in group P, compared with 44, 17 and 17% in group C (p<0.01, Fig. 2, bottom).
Discussion
CresGN, which is defined as extensive crescent formation and a rapid loss of renal function, represents a heterogeneous group of diseases. These diseases have been classified into various subtypes according to clinical, pathological, or immunopathogenetic features (13, (16) (17) (18) .
Recently, we reported that CresGN could be divided into acute and insidious types based on the rate of decline of 1/Cr, i.e., the former type shows an acute onset and a rapid deterioration of renal function and the latter type has a rather indolent clinical course (4). Pathologically, the acute type is characterized by a predominance of cellular crescents and mild interstitial fibrosis, which have been reported to indicate a good prognosis (6, (18) (19) (20) . In contrast, the insidious type shows different crescent phases simultaneously and extensive fibrosis of the interstitium. In this study, the improvement rate with conventional therapy was greater in the acute type (8/10, 80%) than in the insidious type (1/9, 11%, p<0.05), and the renal survival rate tended to be higher in the acute type (p=0.09). These findings suggest that conventional therapy maynot produce satisfactory results in patients with the insidious type of CresGN. Although the exact mechanismof action of pulse methylprednisolone is still unclear, the pulse therapy exerts potent immunosuppressive and anti-inflammatory effects on active glomerular diseases (21, 22) . In the absence of prospective randomized trials, some retrospective studies were suggestive of the effectiveness of pulse therapy in CresGN (5-12). However, it is known that pulse therapy can be associated with lifethreatening complications such as cerebrovascular accidents (23) and arrhythmia (24), in addition to those observed with conventional corticosteroid therapy. Sakemi et al (25) reported worsening of renal function following pulse therapy. Therefore, pulse therapy should be performed cautiously in strictly
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The present study showed that in patients with acute-type CresGN, pulse therapy did not increase either the improvement rate or the renal survival rate. Onthe other hand, in patients with insidious-type disease, the improvementrate was higher with pulse therapy (9/15, 60%) than with conventional therapy ( 1/9, 11%, p<0.05), and the renal survival rate was also higher in group P than in group C (p<0.01) in spite of the lack of differences in clinical or pathological parameters between the two therapy groups. Nomajor complications were observed during or after pulse therapy. These clinical findings suggest that the effects of pulse therapy may be superior to those of conventional therapy in the insidious type ofCresGN but not in the acute type. Moreover, follow-up biopsies in 6 improved patients of group P revealed a significant decrease in the percentage of crescentic glomeruli from 89.5 ± 5.4 to 70.1 ± 7.6% (p<0.01) and a disappearance of cellular crescents in all but one patient. These results suggest that pulse therapy can almost completely suppress the formation of new crescents, i.e., disease activity, indicating the effectiveness of pulse therapy from a pathological viewpoint.
It is generally believed that patients with significant glomerulosclerosis and fibrocellular or fibrous crescents are less likely to respond to immunosuppressive treatment ( 19, 20) . O' Neill et al (6) reported that nonresponders to pulse therapy were characterized histologically by considerable fibrosis of the crescents, glomeruli and interstitium. However, our results, although obtained in a limited number of patients, strongly suggest that CresGN with linearly decreasing 1/Cr, even if gradual, and the presence of cellular crescents, even if only a few, may still benefit from pulse therapy instead of conventional therapy.
In conclusion, it seems possible to state that in CresGN1/Cr maybe one of the simple but very useful clinical parameters for predicting the effect of treatment and selecting the subset of patients for whommethylprednisolone pulse therapy is appropriate. This study also has limitations, as the analysis is retrospective and patients with various underlying diseases are included. In this study, the insidious type, in which the effects of pulse therapy were superior to those of conventional therapy, showed no differences in the incidence of underlying diseases between the two therapy groups. However, in order to draw more definite conclusions, it would be necessary to investigate the effects of pulse therapy in patients with the same underlying etiology prospectively.
In rapidly progressive glomerulonephritis, a relapse after prolonged remission has been reported (26, 27) , and in this study some improved patients treated with pulse therapy ultimately progressed to end-stage renal failure. Therefore, more studies are required to define the optimal pulse therapy.
